Bifogade filer
Kurs
+2,99%
Likviditet
1,10 MSEK
Kalender
Est. tid* | ||
2025-11-11 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-12 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-23 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2025-05-22 | - | Årsstämma |
2025-05-13 | - | Kvartalsrapport 2025-Q1 |
2025-02-11 | - | Bokslutskommuniké 2024 |
2024-11-12 | - | Kvartalsrapport 2024-Q3 |
2024-08-13 | - | Kvartalsrapport 2024-Q2 |
2024-05-15 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2024-05-14 | - | Årsstämma |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-02-13 | - | Bokslutskommuniké 2023 |
2023-11-07 | - | Kvartalsrapport 2023-Q3 |
2023-10-09 | - | Extra Bolagsstämma 2023 |
2023-08-03 | - | Kvartalsrapport 2023-Q2 |
2023-05-24 | - | Split MOB 10:1 |
2023-05-17 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2023-05-16 | - | Årsstämma |
2023-05-09 | - | Kvartalsrapport 2023-Q1 |
2023-02-07 | - | Bokslutskommuniké 2022 |
2022-11-08 | - | Kvartalsrapport 2022-Q3 |
2022-08-09 | - | Kvartalsrapport 2022-Q2 |
2022-05-17 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2022-05-16 | - | Årsstämma |
2022-05-10 | - | Kvartalsrapport 2022-Q1 |
2022-05-03 | - | Extra Bolagsstämma 2022 |
2022-02-08 | - | Bokslutskommuniké 2021 |
2021-11-09 | - | Kvartalsrapport 2021-Q3 |
2021-08-10 | - | Kvartalsrapport 2021-Q2 |
2021-05-11 | - | Kvartalsrapport 2021-Q1 |
2021-03-31 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2021-03-30 | - | Årsstämma |
2021-02-09 | - | Bokslutskommuniké 2020 |
2020-12-01 | - | Extra Bolagsstämma 2020 |
2020-05-12 | - | Kvartalsrapport 2020-Q3 |
2020-02-11 | - | Kvartalsrapport 2020-Q2 |
2019-11-19 | - | Kvartalsrapport 2020-Q1 |
2019-11-04 | - | Inlösen MOB 46.5 |
2019-10-31 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2019-10-30 | - | Årsstämma |
2019-08-29 | - | Bokslutskommuniké 2019 |
2019-05-16 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2019-05-15 | - | Årsstämma |
2019-05-14 | - | Kvartalsrapport 2019-Q1 |
2019-03-15 | - | Extra Bolagsstämma 2019 |
2019-02-12 | - | Bokslutskommuniké 2018 |
2018-11-06 | - | Kvartalsrapport 2018-Q3 |
2018-08-07 | - | Kvartalsrapport 2018-Q2 |
2018-05-16 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2018-05-15 | - | Årsstämma |
2018-05-08 | - | Kvartalsrapport 2018-Q1 |
2018-02-13 | - | Bokslutskommuniké 2017 |
2017-11-13 | - | Kvartalsrapport 2017-Q3 |
2017-08-08 | - | Kvartalsrapport 2017-Q2 |
2017-05-17 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2017-05-16 | - | Årsstämma |
2017-05-09 | - | Kvartalsrapport 2017-Q1 |
2017-02-14 | - | Bokslutskommuniké 2016 |
2016-11-08 | - | Kvartalsrapport 2016-Q3 |
2016-08-09 | - | Kvartalsrapport 2016-Q2 |
2016-05-19 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2016-05-18 | - | Årsstämma |
2016-05-10 | - | Kvartalsrapport 2016-Q1 |
2016-02-17 | - | Bokslutskommuniké 2015 |
2015-11-10 | - | Kvartalsrapport 2015-Q3 |
2015-08-11 | - | Kvartalsrapport 2015-Q2 |
2015-05-12 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2015-05-11 | - | Årsstämma |
2015-05-11 | - | Bokslutskommuniké 2014 |
2015-05-11 | - | Kvartalsrapport 2015-Q1 |
2015-02-27 | - | Bokslutskommuniké 2014 |
2014-11-14 | - | Kvartalsrapport 2014-Q3 |
2014-08-13 | - | Kvartalsrapport 2014-Q2 |
2014-05-14 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2014-05-13 | - | Årsstämma |
2014-05-13 | - | Kvartalsrapport 2014-Q1 |
2014-02-20 | - | Bokslutskommuniké 2013 |
2013-11-05 | - | Kvartalsrapport 2013-Q3 |
2013-08-06 | - | Kvartalsrapport 2013-Q2 |
2013-05-21 | - | Analytiker möte 2013 |
2013-05-21 | - | Kvartalsrapport 2013-Q1 |
2013-04-24 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2013-04-23 | - | Årsstämma |
2013-03-13 | - | 15-7 2013 |
2013-02-05 | - | Bokslutskommuniké 2012 |
2012-11-19 | - | Extra Bolagsstämma 2012 |
2012-10-25 | - | Kvartalsrapport 2012-Q3 |
2012-09-20 | - | Kapitalmarknadsdag 2012 |
2012-08-28 | - | Kvartalsrapport 2012-Q2 |
2012-06-11 | - | 15-7 2012 |
2012-04-24 | - | X-dag ordinarie utdelning MOB 0.00 SEK |
2012-04-23 | - | Årsstämma |
2012-04-23 | - | Kvartalsrapport 2012-Q1 |
2012-02-09 | - | Bokslutskommuniké 2011 |
2011-11-29 | - | 15-7 2011 |
2011-10-28 | - | Kvartalsrapport 2011-Q3 |
2011-08-12 | - | Kvartalsrapport 2011-Q2 |
2011-04-18 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
STOCKHOLM, June 30th, 2025, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 48,712,067. The 832,213 newly issued shares are held by the company to secure its commitments under the incentive program.
As per June 30th, 2025, the total number of shares in Moberg Pharma AB (publ) amounts to 48,712,067. All shares are common shares. The total number of votes are 48,712,067. The increase in the number of shares and votes results from an issue of 832,213 class C shares. The newly issued class C shares have been repurchased and, by virtue of the conversion clause in the articles of association, converted to common shares. As per June 30th, 2025, the company holds 1,711,440 common shares. The shares are intended to ensure fulfilment of commitments under the incentive program.
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, telephone: +46 76 - 805 82 88, e-mail: mark.beveridge@mobergpharma.se
About this information
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on June 30th, 2025, at 8:00 am CET.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).